FindTrial
Sign In

Evaluation of efficacy and safety of granulocyte colony-stimulating factor in the treatment of patients with low ovarian reserve: a multicenter, randomized, double-blind, placebo-controlled clinical trial

Evaluation of efficacy and safety of granulocyte colony-stimulating factor in the treatment of patients with low ovarian reserve: a multicenter, randomized, double-blind, placebo-controlled clinical trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200062412
Enrollment
Unknown
Registered
2022-08-05
Start date
2023-04-01
Completion date
Unknown
Last updated
2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diminished ovarian reserve

Interventions

Experimental group:G-CSF
Control group:Normal saline

Sponsors

Lanzhou University Second Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. Voluntary participation, understanding and signing of informed consent; 2. In line with IVF/ICSI indications; 3. Conform to one of the three can be: (1) 1.10 <= FSH <= 20; (2) Antral follicles <= 7; (3) AMH <= 2.0; 4. Aged 20-40 years; 5. PPOS program to promote ovulation.

Exclusion criteria

Exclusion criteria: 1. Contraindications of IVF/ICSI treatment; 2. Patients with high ovarian response and normal response; 3. Dydrogesterone and G-CSF contraindications.

Design outcomes

Primary

MeasureTime frame
Optimal embryo rate;—

Secondary

MeasureTime frame
Oocyte acquisition rate;Transplantable embryo rate;MII oocyte rate;—

Countries

China

Contacts

Public ContactWang Fang

Lanzhou University Second Hospital

ery_fwang@lzu.edu.cn+86 13919302888

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 7, 2026